Table 2

Antitumor effectiveness of triple mIL-12 gene electrotransfer alone or combined with irradiation on SA-1 sarcoma
Therapeutic group N DT (days; AM ± SE)* GD (days; AM ± SE)** Cures(%; n) SC resistance (n)#
Control 10 3.4 ± 0.4 - 0
3× EP 10 6.0 ± 1.0 2.7 ± 1.0 0
3× dsRed 10 3.1 ± 0.3 −0.3 ± 0.3 0
3× EGT dsRed 12 6.8 ± 0.8 3.4 ± 0.8 8.3 (1/12) 1/1
3× mIL-12 13 5.2 ± 1.3 1.9 ± 1.3 0
3× EGT mIL-12 14 17.7 ± 5.4 14.3 ± 5.4 50.0 (7/14) 7/7
IR 10 Gy 10 8.1 ± 1.5 4.8 ± 1.5 0
3× EP + IR 11 13.1 ± 1.9 9.7 ± 1.9 27.3 (3/11) 3/3
3× dsRed + IR 12 9.9 ± 1.8 6.5 ± 1.8 16.7 (2/12) 2/2
3× EGT dsRed + IR 12 25.7 ± 4.8 ‡§ 22.3 ± 4.8 25.0 (3/12) 3/3
3× mIL-12 + IR 14 10.2 ± 1.7 6.9 ± 1.7 7.1 (1/14) 1/1
3× EGT mIL-12 + IR 15 43.1 ± 28.8 ‡§ 39.8 ± 28.8 86.7 (13/15) 13/13

Therapeutic groups: 10 Gy single dose irradiation (IR), triple electric pulse application alone (3× EP) or combined with irradiation (3× EP + IR), triple intratumoral injection of plasmid DNA coding for mIL-12 or dsRed alone (3× mIL-12, 3x dsRed) or combined with irradiation (3× mIL-12 + IR, 3× dsRed + IR), triple mIL-12 or dsRed gene electrotransfer alone (3× EGT mIL-12, 3× EGT dsRed) or combined with irradiation (3× EGT mIL-12 + IR, 3× EGT dsRed + IR).

N - Number of all mice in the group.

* - Tumor doubling time - only mice with tumors were included in calculation.

** - Tumor growth delay - only mice with tumors were included in calculation.

 - Cures were determined 100 days after the treatment.

# - Resistance to secondary challenge – number of cured mice that were resistant to secondary challenge is shown.

 - Statistical significant difference compared to control group (p < 0.05).

§ - Statistical significant difference compared to IR 10 Gy (p < 0.05)

Sedlar et al.

Sedlar et al. BMC Cancer 2013 13:38   doi:10.1186/1471-2407-13-38

Open Data